IE
NBIX icon

Israel Englander’s Neurocrine Biosciences NBIX Stock Holding History

Israel Englander’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,600
Closed -$5.15M – 6180
2025
Q1 		$5.15M Buy
46,600
+39,500
+556% +$5M ﹤0.01% 2831
2024
Q4 		$969K Buy
+7,100
New +$878K ﹤0.01% 4224
2024
Q3 		– Sell
-107,500
Closed -$14.8M – 6347
2024
Q2 		$14.8M Buy
+107,500
New +$14.7M 0.01% 1751
2022
Q1 		– Sell
-60,000
Closed -$5.11M – 7278
2021
Q4 		$5.11M Sell
60,000
-73,700
-55% -$6.78M ﹤0.01% 2888
2021
Q3 		$12.8M Sell
133,700
-16,300
-11% -$1.54M 0.01% 1763
2021
Q2 		$14.6M Hold
150,000
– – 0.01% 1500
2021
Q1 		$14.6M Buy
150,000
+138,800
+1,239% +$14.6M 0.01% 1396
2020
Q4 		$1.07M Buy
+11,200
New +$1.08M ﹤0.01% 3695
2019
Q3 		– Sell
-50,000
Closed -$4.22M – 4424
2019
Q2 		$4.22M Hold
50,000
– – 0.01% 1909
2019
Q1 		$4.41M Buy
+50,000
New +$4.18M 0.01% 1862
2017
Q1 		– Sell
-80,000
Closed -$3.1M – 3724
2016
Q4 		$3.1M Buy
80,000
+30,000
+60% +$1.36M 0.01% 1638
2016
Q3 		$2.53M Hold
50,000
– – ﹤0.01% 1799
2016
Q2 		$2.27M Buy
+50,000
New +$2.3M 0.01% 1718
2015
Q4 		– Sell
-500,000
Closed -$19.9M – 3662
2015
Q3 		$19.9M Buy
500,000
+200,000
+67% +$9.67M 0.04% 567
2015
Q2 		$14.3M Buy
+300,000
New +$12.7M 0.03% 776
2013
Q4 		– Sell
-75,400
Closed -$854K – 3655
2013
Q3 		$854K Sell
75,400
-14,900
-17% -$205K ﹤0.01% 2215
2013
Q2 		$1.21M Buy
+90,300
New +$1.11M ﹤0.01% 1871

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's NBIX Position: Q2 2026 in Review

Israel Englander reduced its Neurocrine Biosciences (NBIX) stake by 99% in Q2 2026, selling an estimated $183M and leaving 11,585 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3841.

Israel Englander first reported a position in NBIX in Q2 2013 and has held it in 49 quarters since. The position peaked at $164M in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Israel Englander held 11,585 shares of Neurocrine Biosciences worth $1.95M as of Q2 2026.
  • Israel Englander sold 1,235,862 Neurocrine Biosciences shares in Q2 2026, an estimated $183M.
  • Neurocrine Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3841 holding.
  • Israel Englander first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 49 quarters since.
  • Israel Englander's Neurocrine Biosciences position peaked at $164M in Q1 2026.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.